This registration page is for a Galderma virtual promotional meeting for UK HCPs. Prescribing information will be available at the meeting. Click here for full prescribing information and adverse events reporting.
NEMLUVIO is indicated for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.
NEMLUVIO is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Putting the Atopic Dermatitis Patient at the Centre: Integrating Clinical Evidence, Real World Experience and Homecare Supported Nursing
19 May 2026 18:00 – 19:00
Speaker:
Lucy Moorhead – Nurse Consultant, Guys and St Thomas NHS Foundation Trust
Agenda:
• Deep dive into the clinical evidence for NEMLUVIO® ▼ (nemolizumab) including long-term data – Lucy Moorhead
• Real World Evidence and Practical Considerations for Nurses – Lucy Moorhead
• Homecare Q&A – Lisa Wasden and Sarah Powell (Galderma Homecare Team)
• Interactive Q&A – Lucy Moorhead
To help focus the discussion during this webinar, we would like to gauge current awareness and understanding of the Patient Support Programme (PSP) supported by Galderma, including current usage in practice and your clinical perspective.
We would invite you to complete this short pre‑webinar survey on your current experience(s) and confidence with the NEMLUVIO Homecare Pathway. Take the survey
Adverse events should be reported.
Adverse Event Reporting for the UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to Galderma (UK) Ltd E-mail medinfo.uk@galderma.com, Tel: +44 (0)300 3035674
GB-NLV-2600122 | May 2026